These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2060550)

  • 1. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.
    Lemmer B; Scheidel B; Blume H; Becker HJ
    Eur J Clin Pharmacol; 1991; 40(1):71-5. PubMed ID: 2060550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronopharmacology of oral nitrates in healthy subjects.
    Scheidel B; Lemmer B
    Chronobiol Int; 1991; 8(5):409-19. PubMed ID: 1818789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical chronopharmacology of oral nitrates.
    Lemmer B; Scheidel B; Stenzhorn G; Blume H; Lenhard G; Grether D; Renczes J; Becker HJ
    Z Kardiol; 1989; 78 Suppl 2():61-3; discussion 64-7. PubMed ID: 2588762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
    Sundberg S; Lehtonen L
    Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms].
    Merz PG; Thürmann P; Harder S
    Arzneimittelforschung; 1992 Jan; 42(1):21-4. PubMed ID: 1586375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.
    Wagner F; Siefert F; Trenk D; Jähnchen E
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S53-9. PubMed ID: 2354713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
    Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
    Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
    Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin.
    Parker JD
    J Cardiovasc Pharmacol; 1996 Nov; 28(5):631-8. PubMed ID: 8945675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
    Waller DG
    J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
    Muck B; Bonn R; Rietbrock N
    Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
    Thomson AH; Miller SH; Green ST; Whiting B
    Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
    Baxter T; Eadie CJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
    Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
    J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.